The US Food and Drug Administration approved Merck & Co.’s Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infa
In the week that Merck & Co.’s competing respiratory syncytial virus (RSV) antibody, clesrovimab, could get US approval , Sanofi and partner AstraZeneca are bringing forward the shipping of their
“This is the time to stand up together and say “no” to what the [US] Administration is doing,” said a pharmaceutical industry executive during a January 2025 conference call. Since then, President Tru
The Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai